Sort   by:  
 Page size 
ProteomicsDigenic inheritance of mutations in EPHA2 and SLC26A4 in Pendred syndrome
Enlarged vestibular aqueducts (EVA) is one of the most commonly identified inner ear malformations in hearing loss patients including Pendred syndrome. While biallelic mutations of the SLC26A4 gene, encoding pendrin, causes non-syndromic hearing loss with EVA or Pendred syndrome, a considerable numb...
ORGANISM(S): Homo sapiens (Human) 
2020-04-22 | PXD017011 | Pride
Pendred syndrome Epha2 Ephrin-b2 
ProteomicsIdentification of proteins interacted with EphA2 in nasopharyngeal carcinoma cells by LC-MS / MS
To search proteins that interact with EphA2, EphA2 interactors were coimmunoprecipitated with anti-EphA2 antibody from 5-8F NPC cell extracts, separated on SDS-PAGE and stained with Coomassie blue , and non-immune IgG antibody instead of anti-EphA2 antibody served as control. All bands were excised,...
ORGANISM(S): Homo sapiens (Human) 
2021-09-08 | PXD015242 | Pride
Epha2 Nasopharyngeal carcinoma Lc-ms / ms 
GenomicsTranscriptional profiling of EPHA2-WT and EPHA2-KO pancreatic tumor cells
Transcriptional profiling of EPHA2-WT and EPHA2-KO pancreatic tumor cells
PRJNA491946 | ENA
GenomicsEphA2-SE-KO RNA-seq
EphA2-SE-KO RNA-seq
PRJNA668532 | ENA
ProteomicsNon-canonical EphA2 signaling is a driver of tumor-endothelial cell interactions and metastatic dissemination in BRAF inhibitor resistant melanoma
Acquired BRAF/MEK inhibitor resistance in melanoma results in a new transcriptional state associated with increased risk of metastasis. Here, we identified non-canonical EphA2 signaling as a driver of the resistance-associated metastatic state. We used mass spectrometry-based proteomic and phenotypi...
ORGANISM(S): Homo sapiens (Human) 
2020-11-18 | PXD020250 | Pride
Phosphotyrosine. ephrin a2 Melanoma Braf inhibitor Drug resistance 
ProteomicsNon-canonical EphA2 signaling is a driver of tumor-endothelial cell interactions and metastatic dissemination in BRAF inhibitor resistant melanoma: Phosphoproteomics
Acquired BRAF/MEK inhibitor resistance in melanoma results in a new transcriptional state associated with increased risk of metastasis. Here, we identified non-canonical EphA2 signaling as a driver of the resistance-associated metastatic state. We used mass spectrometry-based proteomic and phenotypi...
ORGANISM(S): Homo sapiens (Human) 
2020-11-18 | PXD020241 | Pride
Melanoma Phosphoproteomics. ephrin a2 Braf inhibitor Drug resistance 
ProteomicsNon-canonical EphA2 signaling is a driver of tumor-endothelial cell interactions and metastatic dissemination in BRAF inhibitor resistant melanoma: Expression Proteomics
Acquired BRAF/MEK inhibitor resistance in melanoma results in a new transcriptional state associated with increased risk of metastasis. Here, we identified non-canonical EphA2 signaling as a driver of the resistance-associated metastatic state. We used mass spectrometry-based proteomic and phenotypi...
ORGANISM(S): Homo sapiens (Human) 
2020-11-18 | PXD020242 | Pride
Melanoma Braf inhibitor Expression proteomics. ephrin a2 Drug resistance 
GenomicsRNA-seq data for EphA2 knockdown in Huh7 cells
RNA-seq data for EphA2 knockdown in Huh7 cells
PRJNA595083 | ENA
GenomicsKPPC cells cells treated with EphA2 inhibitor
KPPC cells cells treated with EphA2 inhibitor
PRJNA1243467 | ENA
ProteomicsEphA2 regulates vascular permeability and prostate cancer metastasis via modulation of cell junction protein phosphorylation
Prostate cancer morbidity and mortality obviate a need for more effective targeted therapies. One potential target is EphA2, although paradoxically, pro- and anti-oncogenic effects have been shown to be mediated by EphA2. We demonstrate that unique activating and blocking EphA2-targeting monoclonal ...
ORGANISM(S): Homo sapiens (Human) 
2024-11-11 | PXD053835 | Pride
Afadin Shb Phosphoproteomics Epha2 Silac Eph receptor 
Sort   by:  
 Page size